1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Data Coordinating Center for the Aging and Alzheimer's Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH) - National Institute on Aging (NIA). Supports the establishment of a data coordinating center focused on aging, the aging brain, neurodegenerative conditions, and the Alzheimer's Disease and Related Dementias (AD/ADRD) mouse brain atlas to advance translational open-science infrastructure.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official RFP to help you evaluate fit faster.
Aging and Alzheimer's Disease Research Grant USA | ScientifyResearch National Institutes of Health (NIH) Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed) (USA) create free account for link to funder page join to access premium tools The Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed) funding from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), is open to researchers in the USA.
This call invites applications proposing a Data Coordinating Center that integrates and disseminates multiscale mouse brain datasets for the aging and Alzheimer’s disease (AD) research community.
The Data Coordinating Center will establish the Aging and AD Mouse Brain Atlas (AD-MBA), which will serve as a central, unified research resource for multi-omic and connectomic mouse brain datasets emerging from the NIA AD Multimodal Atlas Projects (AD-MAPs). The grant provides funding for up to 5 years. Funding opportunity number: RFA-AG-27-010 Applications open on October 10, 2026 and close on November 10, 2026.
Expert guidance for your application success Coming soon … For more visit our page Courses & Workshops National Alzheimer’s Coordinating Center (U24 Clinical Trial Not Allowed | USA) Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) (R03 Clinical Trial Optional) (USA) Diagnostics Accelerator: Digital Biomarkers Program (Alzheimer's disease | worldwide) Alzheimer’s Association Research Grant For All (AARGA) Program (worldwide) All neurology research funding Coming soon … For more experts visit our page coaching & consultation Prev Previous Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required) (USA) Next Paul B.
Beeson Emerging Leaders Career Development Award in Aging (K76 | USA) Next The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes.
Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you. The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage {vendor_count} vendors The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes. Manage {vendor_count} vendors
According to the current listing, eligibility includes: Higher education institutions, non-profits, for-profit organizations, public/state controlled institutions, and local governments. Confirm the full requirements in the official notice before applying.
Applications for Data Coordinating Center for the Aging and Alzheimer's Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed) are due November 10, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Data Coordinating Center for the Aging and Alzheimer's Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed) is funded by National Institutes of Health (NIH) - National Institute on Aging (NIA). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
NIH SBIR/STTR Omnibus Solicitation (Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH) - National Institute on Aging (NIA). This omnibus funding opportunity is for investigator-initiated small business research projects focused on aging-related innovations, including technologies for older adults' health, well-being, and independence. It supports U.S. small businesses for Phase I and II awards.
NIA Expanding Research in AD/ADRD (ERA) Postbaccalaureate Research Education Program is sponsored by National Institutes of Health (NIH) - National Institute on Aging (NIA). This program aims to enhance the research workforce by providing intensive research experiences for recent graduates. It supports early-stage investigators in Alzheimer's Disease and related dementias, addressing a critical shortage of researchers in the field.
NIH's RFI on administrative burden (NOT-OD-26-118) takes comments through December 8, 2026. It asks seven questions, lists eight reforms already made, and warns that responses may be posted unredacted. Here is what NIH is really asking for, what it can and cannot change alone, and how researchers and research offices should respond.
Read articleOn November 2, 2026, NIH released NOT-OD-27-006, a draft update to its Policy for Data and Safety Monitoring. As summarized by Harvard's research integrity office, the draft would extend risk-based monitoring from clinical trials to all NIH-supported clinical research, drop the blanket DSMB requirement for Phase 3 and multi-site trials, and require an NIH-approved monitoring plan scaled to risk, effective for applications six months after the final policy. Comments are due January 6, 2027. What it changes and how to respond.
Read articleR&D World's count of NIH RePORTER data shows 13,686 new awards in FY2026, up 21% from 11,272 in FY2025, while total extramural grants fell to about 56,600. New R01s hit 4,960. What the split means for FY2027 applicants.
Read article